WEST LAFAYETTE, IN, September 8, 2022Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), is pleased to announce Dr. Harutyun (Harut) Avsaroglu as the Company’s Executive Director, Global Laboratory Animal Resources.

Coming to Inotiv most recently from Ross University School of Veterinary Medicine, Dr. Avsaroglu is a laboratory animal veterinarian with twenty years of progressive leadership experience in research animal facilities, and working knowledge and experience in vivarium management under European and U.S. regulatory environments.


Dr. Harut Avsaroglu, Executive Director, Global Laboratory Animal Resources

Dr. Avsaroglu is a globally-recognized expert in laboratory animal use and care, and has a track record of commitment to the highest industry standards. He has served as advisor and member of several animal use committees within Europe and the Americas, and has focus and passion for continuous, on-the-job training and education for animal welfare experts.

Dr. Avsaroglu’s responsibilities as Executive Director, Global Laboratory Animal Resources, include:

  • 🔸Overseeing the establishment and maintenance of animal health programs to ensure the high standards of laboratory animal care expected by Inotiv and all global regulatory standards
  • 🔸Providing training and assistance to husbandry, technical, and animal welfare staff on humane and up-to-date methods of animal care and use
  • 🔸Collaborating on growth and outreach strategies for veterinary and animal welfare recruitment and retention

John Sagartz, DVM, PhD, DACVP, Inotiv’s Chief Strategy Officer, commented, “With the employment of veterinarians projected to grow 17% from 2020 to 2030, we need industry recognized leaders and mentors who are eager to attract and recruit this pool of veterinary and animal welfare talent. We also need individuals who are strong advocates of animal welfare and view their work with animals in biomedical research as a privilege. I believe Dr. Avsaroglu is the leader Inotiv needs to meet these important imperatives.”

About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company Contact   Investor Relations
Inotiv, Inc.   The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer   Devin Sullivan
(765) 497-8381   (212) 836-9608
INSIGHTS, Keep up-to-date with the latest industry thinking and scientific insights


Keep up-to-date with the latest industry thinking and scientific insights

Explore today Explore today  

More than 90 years of working together, to build a healthier and safer world  


Explore our history Explore our history  

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now